Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients

NCT07840196 is registered in ClinicalTrials.gov with NovaGo Therapeutics AG as lead sponsor.

NCT NCT07840196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07840196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients
Lead sponsor
NovaGo Therapeutics AG
Phase
Phase 1
Overall status
Recruiting
Start date
August 5, 2026
Completion date
July 31, 2029
Enrollment
120 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury (sci), spinal cord diseases, spinal cord injuries, trauma nervous system